Fly News Breaks for June 12, 2015
VRTX
Jun 12, 2015 | 08:40 EDT
JMP Securities believes that Phase 3 data on Vertex's Orkambi in cystic fibrosis showed that the improvement in lung function of patients taking the drug was impressive. The firm says that the rest of the data was also supportive of the drug's outlook. It keeps a $152 price target and Outperform rating on Vertex.
News For VRTX From the Last 2 Days
There are no results for your query VRTX